Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Aims to become India’s leading cancer testing company
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Subscribe To Our Newsletter & Stay Updated
